Degron Therapeutics
Degron Therapeutics is a biotech company in San Diego, United States, founded in 2021. It has raised $62.0M across 2 rounds, most recently a $40.0M Extension Round in May 2026.
Global leader in molecular glue degrader medicines
- Headquarters
- San Diego, California
- Employees
- 51–200
- Founded
- 2021
- Business Model
- B2B
- Website
- degronsci.com
- Total Funding
- $62.0M
- Last Round
- $40.0M Extension RoundMay 2026
- Rounds
- 2
Totals include recorded grants and other qualifying funding, not just equity. What counts toward funding.
Indexed holds 2 funding rounds and 6 investors for this company. The full record is or through the API.
About
Degron Therapeutics is a clinical-stage biotech developing molecular glue degrader drugs targeting previously undruggable proteins in oncology, inflammation, and metabolic disease. Founded in 2021, the company has advanced its lead asset DEG6498, a first-in-class HuR-targeting MGD, into Phase 1 clinical trials. Headquartered in San Diego with operations in Shanghai.
Summary
It lists 51–200 employees. It has raised $62.0M in total across 2 rounds, most recently a $40.0M Extension Round in May 2026. Investors include Lapam Capital, Med-Fine Capital and DYEE Capital.
Funding History
May 2026
Sign up to see all 2 events
Funding: Series A through Extension Round. Amounts, valuations, and investors where available.
Investors
Similar Companies
China's leading blood products manufacturer
One of the world's largest contract research organizations (CROs), providing end-to-end clinical ...
Global contract research organization providing comprehensive drug development and laboratory ser...
Specialty pharmaceutical company
Appears in
Your company? Embed this profile
Add the live badge to your site — it stays current as your funding data updates.
<a href="https://indexed.vc/companies/degron-therapeutics"><img src="https://indexed.vc/api/badge/company/degron-therapeutics" alt="Degron Therapeutics on Indexed.vc" width="260" height="76" /></a>